Our headquarters are located at 5956 Sherry Lane, Suite 650, Dallas, Texas 75225. The main office phone number is (972) 687-7250.
Our common stock is traded on the NASDAQ Capital Market under the symbol SWKH. Our CUSIP number is 78501P203.
Please refer to our latest SEC filings, which are available at investors.swkhold.com/sec-filings and www.sec.gov for available share information.
SWK’s fiscal year end is December 31st.
Computershare
462 South 4th Street
Suite 1600
Louisville, KY 40202
(800) 962-4284
Outside legal counsel: Goodwin Procter LLP – Justin Platt – The New York Times Building – 620 Eighth Avenue, New York, NY 10018
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information section of our Investor Relations webpage or directly from the SEC at www.sec.gov.
SWK Holdings Corporation was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its life science focused specialty finance business. In August 2019, the Company commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business with the acquisition of Enteris BioPharma, Inc.
IR Labs Inc. is SWK’s investor relations firm. For additional information, please contact:
Ira M. Gostin, MBA, APR
Vice President, Investor Relations
ira@irlabs.ca
775-391-0213
SWK’s officers and directors can be found in the “About SWK” section of our website.
5956 Sherry Lane, Suite 650
Dallas, Texas 75225
Phone: 972.687.7250
Fax: 972.687.7255
For Investors:
investorrelations@swkhold.com
For Capital Alternatives:
inquiries@swkhold.com
For Career Opportunities:
recruiting@swkhold.com